PYX Resources: Achieving volume and diversification milestones. Watch the video here.
1.5m in orders in the first 6 months. We have no way to know if they were all delivered and invoiced in 2023.
They have to announce results by the end of June so not long to wait now.
Sales up to the end of June 2023 for H1 were 550k. I don't understand where the 750k comes from?
Https://www.gloucestershirelive.co.uk/news/health/20p-day-supplement-boosts-brain-9135552
Could Opti cash in on these benefits?
We know the standard royalty % with the US partner is 5% plus another 5% for the MTA partners. I think it's safe to assume that OptiBiotix royalty with DSM Firmenich is 5%.
I don't think it'll be too far off that figure
The actual text was > 100k tonnes and this is for only DSM Firmenich.
The US partner will most likely have similar forecast with any few of the big 11 global MTA partners signing up for sweetbiotix. I think this is in the early stages of a major re-rate of the sp.
Original US sweetbiotix deal -
OptiBiotix will receive a modest six-figure payment from the Company on signing the agreement and at 12 monthly intervals until product launch. Additional similar payments will be due on product launch plus royalties on all future product sales.
Does this mean another payment on the launch of the first sweetbiotix product?
Https://www.symbiopharm.de/produkte/symbiolife-praezisionsprobiotika/symbiolife-cholesterin-control
The rns states...
SymbioPharm has introduced the CholBiome® CH formulation as a premium pharmacy supplement solution across targeted regions...
Sounds like the formulation is already on sale?
Presentation at ProBiota 2024
The Company will be presenting on novel methods to design a range of prebiotic approaches which stimulate the growth of probiotics of commercial interest. These can be used as excipients in probiotic capsules, tablets, and sachets to selectively support the growth of the probiotic and enhance its health benefit